Drug Topics December 24, 2023
Lauren Biscaldi, MS, Managing Editor

Vaccine approvals included two immunizations for RSV and a new pentavalent meningococcal shot.

This year was a year of firsts in the immunization space1: In addition to the first vaccines to protect against lower respiratory tract disease caused by respiratory syncytial virus (RSV) in older adults and the first RSV vaccine for use in pregnant people to protect newborns, 2023 saw the first vaccine for adults at increased risk of exposure to chikungunya virus made its debut. Additional approvals included a new meningococcal vaccine that simplifies a complex immunization schedule.

References

1. 2023 biological license application approvals. FDA. Reviewed November 27, 2023. Accessed November 28, 2023. https://www.fda.gov/vaccines-blood-biologics/development-approval-process-cber/2023-biological-license-application-approvals

2. FDA approves first respiratory syncytial virus (RSV) vaccine. News release. FDA. May...

Today's Sponsors

Venturous
Got healthcare questions? Just ask Transcarent

Today's Sponsor

Venturous

 
Topics: Biotechnology, FDA, Govt Agencies, Pharma, Pharma / Biotech
MHE Week in Review – New PBM Reform Bill, Cardiac Diseases Cost
Deep learning uncovers gene targets and potential drugs to slow brain aging
FDA issues flu vaccine recommendations: 5 respiratory updates
CZI’s Priscilla Chan on ‘Virtual Cells’ AI Models to Cure Diseases
HIMSSCast: The 'genetic revolution' is underway

Share This Article